Newsletters
RB1-Deficient Prostate Tumor Growth and Metastasis Are Vulnerable to Ferroptosis Induction via the E2F/ACSL4 Axis
[Journal Of Clinical Investigation] Researchers showed that RB1-loss/E2F activation sensitized cancer cells to ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, by upregulating expression of ACSL4 and enriching ACSL4-dependent arachidonic acid-containing phospholipids, which are key components of ferroptosis execution.
Expression and Therapeutic Targeting of Trop-2 in Treatment Resistant Prostate Cancer
[Clinical Cancer Research] Scientists observed that Trop-2 can serve as a cell surface target for isolating circulating tumor cells, which may serve as a predictive biomarker for antibody drug conjugates.
CD46 Targeted 212Pb Alpha Particle Radioimmunotherapy for Prostate Cancer Treatment
[Journal Of Experimental & Clinical Cancer Research] Investigators reported the development of a novel CD46-targeted alpha therapy based on the internalizing human monoclonal antibody, YS5.
Inceptor Correlates with Markers of Prostate Cancer Progression and Modulates Insulin/IGF1 Signaling and Cancer Cell Migration
[Molecular Metabolism] Scientists investigated the role of the novel insulin/insulin-like growth factor 1 (IGF1) signaling modulator inceptor in prostate cancer.
Mitochondrial Transplantation: Effects on Chemotherapy in Prostate and Ovarian Cancer Cells In Vitro and In Vivo
[Biomedicine & Pharmacotherapy] Researchers investigated the effect of direct mitochondria transplantation on cancer cell proliferation and chemotherapeutic sensitivity in prostate and ovarian cancer models, both in vitro and in vivo.
The Transmembrane Protein TM4SF3 Interacts with AR and AR-V7 and is Recruited to AR Target Genes
[Endocrinology] Scientists mapped the interaction domains within the androgen receptor (AR) and transmembrane 4 superfamily 3 (TM4SF3) and discovered that TM4SF3 also physically interacted with AR-V7, regulating its protein stability and the viability of castration-resistant prostate cancer cells expressing AR-V7.
CACNA1D Overexpression and Voltage-Gated Calcium Channels in Prostate Cancer during Androgen Deprivation
[Scientific Reports] Researchers showed how hormone therapy affected CACNA1D expression and CaV1.3 function.
[99mTc]Tc-HYNIC-RM2: A Potential SPECT Probe Targeting GRPR Expression in Prostate Cancers
[Nuclear Medicine And Biology] Investigators synthesized a 99mTc-labeled probe and investigated its potential for SPECT imaging of prostate cancer.
Integrating Radium-223 Therapy into the Management of Metastatic Prostate Cancer Care: A Plain Language Summary
[Future Oncology] The authors provide an overview of the current systemic treatments available for metastatic castration-resistant prostate cancer and reviews studies that investigate the optimal timing for the use of radium-22.
Bayer Expands Global Clinical Program for Darolutamide in Prostate Cancer
[Bayer] The new Phase III clinical study, ARASTEP, would investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.
Dr. Ekta Khurana Receives Grant to Study Prostate Cancer Evolution
[Weill Cornell Medicine] Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy.
Gradient to Sectioning CUBE Workflow for the Generation and Imaging of Organoids with Localized Differentiation
[Communications Biology] Researchers presented a workflow for culturing organoids with morphogen gradient using a CUBE culture device, followed by sectioning samples with the CUBE to retain information on gradient direction.